Frazier Life Sciences Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Frazier Life Sciences Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100,430	Closed	-$10.2M	–	55
2023 Q2	$10.2M	Buy	+100,430	New	+$9.5M	0.61%	31

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Frazier Life Sciences Management's RETA Position: Q3 2023 in Review

Frazier Life Sciences Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 100,430 shares — an estimated $10.2M sold.

Frazier Life Sciences Management first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $10.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Frazier Life Sciences Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Frazier Life Sciences Management sold 100,430 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $10.2M.
Frazier Life Sciences Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
Frazier Life Sciences Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $10.2M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.